We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: NLRP3 inflammasome
MedXY News
EnglishTag

NLRP3 inflammasome

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersclinical trialsartificial intelligenceHypertensionCardiologyoncologytype 1 diabetespublic healthMortalitydiabetesAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic Leukemia
Hematology-Oncologytargeted therapyJuvenile myelomonocytic leukemia

Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic Leukemia

By MedXY|Sep 22, 2026

This study identifies an IL-17A/PTGS2/NLRP3 signaling axis as a key driver of immune suppression and myeloproliferation in PTPN11-mutant JMML, demonstrating that combined inflammasome and PTGS2 inhibition with MEK blockade improves survival

Oral NLRP3 Inhibition With Ruvonoflast Produces Rapid, Reversible Suppression of Residual Inflammation in Adults at High Cardiovascular Risk
Cardiology
cardiovascular risk
hsCRP

Oral NLRP3 Inhibition With Ruvonoflast Produces Rapid, Reversible Suppression of Residual Inflammation in Adults at High Cardiovascular Risk

By MedXY|Jun 10, 2026

In a Phase 1b placebo-controlled trial, ruvonoflast markedly reduced hsCRP, IL-6, and fibrinogen over 28 days in adults with obesity, elevated hsCRP, and cardiometabolic risk, supporting further evaluation of oral NLRP3 inhibition in athero

NLRP3 Inflammasome in Hearing Loss: Mechanisms and Emerging Therapeutic Strategies
newsNLRP3 inflammasomepyroptosis

NLRP3 Inflammasome in Hearing Loss: Mechanisms and Emerging Therapeutic Strategies

By MedXY|Nov 4, 2025

The NLRP3 inflammasome plays a central role in inflammation-mediated sensorineural hearing loss (SNHL). Genetic and acquired activation causes cochlear damage through cytokine release and pyroptosis. Targeted therapies, including IL-1 block

NLRP3 Inflammasome and Gut Microbiota-Brain Axis: Emerging Insights into White Matter Injury After Intracerebral Hemorrhage
Clinical UpdatesIntracerebral HemorrhageNLRP3 inflammasome

NLRP3 Inflammasome and Gut Microbiota-Brain Axis: Emerging Insights into White Matter Injury After Intracerebral Hemorrhage

By MedXY|Sep 30, 2025

This article explores how gut microbiota dysbiosis and NLRP3 inflammasome activation contribute to secondary white matter injury post-intracerebral hemorrhage, outlining mechanisms and potential therapeutic strategies.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure